Şunu aradınız:: immuno (İngilizce - Maltaca)

immuno-
mhux

immuno-allergic
allerġika

immuno-suppressive therapy
terapija immunosoppressiva

very rare: immuno-allergic thrombocytopenia
rari ħafna: tromboċito penija immuno- allerġika

(**) antigen content (vp2 protein) by immuno-assay
(**) kontenut tal-antiġen (proteina vp2) permezz ta’ immuno-assay

humira contains the active substance adalimumab, a selective immuno suppressive agent.
humira fih is-sustanza attiva adalimumab li huwa aġent silettiv immuno suppressiv.

this belongs to a group of medicines called “immuno-suppressants”.
dan jagħmel parti minn grupp ta’ mediċini msejħa “immunosoppressanti”.

the method used for identification (colony, hybridization, immuno-blot, etc.);
il-metodu wżat għall-identifikazzjoni (kolonja, ibridizzazzjoni, immuno-blot, eċċ.);

the agar gel immuno-diffusion test shall be carried out according to the following protocol:
it-test għall-immuno-taħlit ta’ agar gel għandu jsir skont il-protokoll li ġej:

(*) antigen content (vp2 protein) by immuno-assay (**) haemolytic units
(*) kontenut tal-antiġen(proteina vp2) bl-immuno-assay (**) unitajiet emolitiċi

myelo-suppression and immuno-suppression were the desired therapeutic effects of the conditioning regimen.
il-mijelosuppressjoni u l-immunosuppressjoni kienu l-effetti terapewtiċi mixtieqa tar-regimen kondizzjonarju.

the risk of infections, including opportunistic infections, and the contraindication for use in immuno-compromised patients.
ir-riskju ta’ infezzjonijiet, li jinkludu infezzjonijiet opportunistiċi u li huwa kontra- indikat għall-użu f’pazjenti li għandhom defiċjenza immunitarja.

fendrix may need to be given at the same time as an injection of hepatitis b “immuno-globulins”.
fendrix jista’ jkollu bżonn jingħata fl-istess ħin ma’ injezzjoni ta’ “immunoglobulini” tal-epatite b.

ciclosporin, tacrolimus and sirolimus, used for after having a transplant, called „immuno- suppressants‟,
ciclosporin, tacrolimus u sirolimus, li jissejħu „immunosoppressanti‟ użati għal wara trapjant,

myelo-suppression and immuno-suppression were the desired therapeutic effects of the conditioning regimen and consequently were not considered undesirable effects.
il-majelosoppressjoni u l-immunosoppressjoni kienu l-effetti terapewtiċi mixtieqa tar-regimen kondizzjonarju u konsegwentement ma ġewx ikkunsidrati bħala effetti mhux mixtieqa.

for the programmes referred to in articles 29 to 33 costs of analyses are reimbursed up to eur 10 per genotyping test, eur 15 per histopathology test, eur 15 per immuno-histochemistry test and eur 15 per elisa test.
għall-programmi li hemm riferenza għalihom fl-artikoli 29 sa 33 in-nefqa ta’ l-analiżi fil-laboratorju hija mħallsa lura sa eur 10 kull genotyping test, eur 15 kull histopathology test, eur 15 kull immuno-histochemistry test u eur 15 kull test eliza.

where the result of the histopathological examination is inconclusive or negative or where the material is autolysed, the tissues shall be subjected to an examination by immunocytochemistry or immuno-blotting, as laid down in the manual.
fejn ir-riżultat ta' l-eżami istopatoloġiku jkun inkonklussiv jew negattiv jew fejn il-materjal ikun awtolizzat, it-tessuti għandhom jiġu soġġettati għal eżami permezz ta' immunoċitokimika jew immuno-blotting kif stabbilit fil-gwida.

bluetongue virus serotype 8 antigen ........................................................................... 2.1 log10 pixels* (*) antigen content (vp2 protein) by immuno-assay
antiġen tal-virus tal-bluetongue tas-serotip 8 ...........................................................> 2.1 log10 pixels * (*) kontenut tal-antiġen(proteina vp2) bl-immuno-assay

.inactivated bluetongue virus serotype 1............................................................... 1.9 log10 pixels * (*) antigen content (vp2 protein) by immuno-assay
serotip 1 tal-virus inattivat tal-bluetongue ........................................................... 1.9 log10 pixels* (*) kontenut tal-antiġen (proteinavp2) permezz ta’ immuno-assay